🇺🇸 FDA
Patent

US 9163236

Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer

granted A61PA61P35/00

Quick answer

US patent 9163236 (Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P35/00